fluorodopa f 18 has been researched along with ANS (Autonomic Nervous System) Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Crews, C; Goldstein, DS; Hallett, M; Hardy, J; Holmes, C; Imrich, R; Lopez, G; Peckham, E; Singleton, A | 1 |
| Brooks, DJ; Burn, DJ; Marsden, CD; Mathias, CJ; Quinn, NP; Rinne, JO | 1 |
| Jankovic, J; Kapadia, AS | 1 |
3 other study(ies) available for fluorodopa f 18 and ANS (Autonomic Nervous System) Diseases
| Article | Year |
|---|---|
Neurocirculatory and nigrostriatal abnormalities in Parkinson disease from LRRK2 mutation.
Topics: Arrhythmias, Cardiac; Autonomic Nervous System Diseases; Baroreflex; Dihydroxyphenylalanine; DNA Mutational Analysis; Genetic Predisposition to Disease; Genotype; Heart; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male; Middle Aged; Myocardium; Neostriatum; Neural Pathways; Parkinson Disease; Positron-Emission Tomography; Protein Serine-Threonine Kinases; Reflex, Abnormal; Substantia Nigra; Valsalva Maneuver | 2007 |
Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy.
Topics: Autonomic Nervous System Diseases; Carbon Radioisotopes; Corpus Striatum; Dihydroxyphenylalanine; Diprenorphine; Dopamine; Female; Fluorine Radioisotopes; Humans; Male; Middle Aged; Olivopontocerebellar Atrophies; Receptors, Opioid; Tomography, Emission-Computed | 1995 |
Functional decline in Parkinson disease.
Topics: Adolescent; Adult; Age of Onset; Aged; Aged, 80 and over; Autonomic Nervous System Diseases; Demography; Dihydroxyphenylalanine; Disease Progression; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Middle Aged; Multiple System Atrophy; Multivariate Analysis; Neurologic Examination; Parkinson Disease; Radiopharmaceuticals; Time Factors | 2001 |